GLUE
Monte Rosa Therapeutics, Inc.
There isn't enough reported data to score GLUE yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
GLUE Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
GLUE's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
GLUE PE Valuation
GLUE has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
GLUE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect GLUE's losses to grow, with revenue declining. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
GLUE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.40 | -489% |
| Q2 2026 | -$1.76 | -540% |
| Q1 2026 | -$1.48 | -1333% |
| Q4 2025 | -$0.46 | +$0.52 |
| Q3 2025 | $0.36 | +$2.18 |
| Q2 2025 | $0.40 | +$2.63 |
| Q1 2025 | $0.12 | +$2.63 |
| Q4 2024 | -$0.98 | +$1.65 |
GLUE has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
GLUE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.4M | +326% |
| Q2 2026 | $9M | -61% |
| Q1 2026 | $4.2M | -95% |
| Q4 2025 | $2.8M | -95% |
| Q3 2025 | $12.8M | +39% |
| Q2 2025 | $23.2M | +394% |
| Q1 2025 | $84.9M | +7882% |
GLUE's revenue is recovering but still below its 2025 peak: $54M last quarter, up 326% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.6% | +255 points |
| Q2 2026 | -548% | -481 points |
| Q1 2026 | -1188% | -1240 points |
| Q4 2025 | -1788% | -1809 points |
| Q3 2025 | -258% | +30 points |
| Q2 2025 | -67% | +628 points |
| Q1 2025 | 52% | +3336 points |
| Q4 2024 | 21% | N/A |
GLUE has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over GLUE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
GLUE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$42.5M | -143% |
| Q2 2026 | -$48.8M | -$12.4M |
| Q1 2026 | -$39.2M | +$7.8M |
| Q4 2025 | -$43.8M | -134% |
| Q3 2025 | $99.8M | +$121.2M |
| Q2 2025 | -$36.4M | -$6.6M |
| Q1 2025 | -$47.1M | -$7.5M |
| Q4 2024 | $128.7M | +361% |
GLUE has burned cash in almost every quarter: −$174M over the past year, against $145M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over GLUE on cash generation, producing positive trailing cash flow while its opponent burns cash.
GLUE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7% | +7.1M shares |
| 1 year | +32% | +26.2M shares |
| 3 years | +118% | +58.8M shares |
| 5 years | +155% | +66.1M shares |
| Available history | +400% | +86.9M shares |
GLUE has 109M diluted shares, up 32% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | $178,000 |
| Q1 2020 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over GLUE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
GLUE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -11.2x | Net Cash |
| Q2 2025 | -2.8x | Net Cash |
| Q1 2025 | -10.4x | Net Cash |
GLUE has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
GLUE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.0 | Neutral |
| Stochastic | 6.7 | Oversold |
GLUE's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
GLUE PE vs Healthcare Sector
| Metric | GLUE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GLUE has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
GLUE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.5 | 11% below |
| 20 week MA | $14.7 | 37% below |
| 50 week MA | $17.0 | 45% below |
| 100 week MA | $11.8 | 21% below |
| 200 week MA | $8.82 | 5.6% above |
GLUE has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
GLUE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $18.9 | $20.9 | +11% |
| 2022 | $20.9 | $7.94 | -62% |
| 2023 | $7.94 | $5.65 | -29% |
| 2024 | $5.65 | $7.06 | +25% |
| 2025 | $7.06 | $17.3 | +145% |
| 2026 YTD | $17.3 | $9.31 | -46% |
GLUE's yearly returns have swung widely, from +145% in 2025 to −62% in 2022. It's down 46% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over GLUE on returns for 2026, with the stronger performance.